Vitamin variants could combat cancer as scientists unravel B12 secrets

Oct 08, 2012
Vitamin variants could combat cancer as scientists unravel B12 secrets

(Phys.org)—In a development that may lead to new drugs to treat cancer, scientists at the University have discovered the process by which a key vitamin (B12) is made in cells.

A team at the University's School of Biosciences led by Professor Martin Warren devised a method that allows them to study how the individual steps for construction are pieced together. B12 is an essential nutrient that plays an important role in the formation of and the maintenance of the nervous system. Deficiencies are associated with anaemia, cardiovascular disorders and dementia.

Using techniques of the new discipline of synthetic biology, researchers engineered a of molecular machines for the construction of the vitamin within bacteria. By varying the length of the , they were able to unravel how the vitamin is manufactured.

Significantly, the team were also able to alter some of the molecular machines on the conveyor belt and change the form of the vitamin that is made. It is hoped that these novel variant forms of the vitamin will act as important to treat diseases such as cancer and infections such as tuberculosis (TB).

The team's research paper An enzyme-trap approach allows isolation of intermediates in cobalamin (vitamin B12) is published in the current edition of the journal Nature .

Professor Warren, who is Head of the School of Biosciences, said: 'This is a really important step forward. Vitamin B12 is a nutrient that is only made by bacteria and is not present in plants. Therefore a significant proportion of the world's population, including vegetarians, are at risk of B12 deficiency.

'Our work will assist in the generation of better ways of making more of this vitamin available and is also permitting us to make new compounds that will literally allow us to throw a spanner in the works of infections such as TB and diseases such as cancer.'

The Kent team worked with several partners including new biotechnology company Cangenix, based at the School of Biosciences, and researchers at Queen Mary, University of London (QM). The research was funded by a research grant from the Biotechnology and Biological Sciences Research Council to Professor Warren and Professor Richard Pickersgill of QM.

Explore further: Scientists make diseased cells synthesize their own drug

add to favorites email to friend print save as pdf

Related Stories

Vitamin B12 may protect the brain in old age

Sep 08, 2008

Vitamin B12, a nutrient found in meat, fish and milk, may protect against brain volume loss in older people, according to a study published in the September 9, 2008, issue of Neurology, the medical journal of the American Academ ...

Vitamin B12 deficiency: Tracking the genetic causes

Aug 26, 2012

Vitamin B12 is essential to human health. However, some people have inherited conditions that leave them unable to process vitamin B12. As a result they are prone to serious health problems, including developmental delay, ...

A breath of fresh air for detecting vitamin B12 deficiency

Jun 23, 2011

Researchers have developed a new test to detect the levels of vitamin B12 using your breath, allowing for a cheaper, faster, and simpler diagnosis that could help to avoid the potentially fatal symptoms of B12 deficiency.

Vitamin B12 may reduce risk of Alzheimer's disease

Oct 18, 2010

A new study shows that vitamin B12 may protect against Alzheimer's disease, adding more evidence to the scientific debate about whether the vitamin is effective in reducing the risk of memory loss. The research will be published ...

Recommended for you

Scientists make diseased cells synthesize their own drug

7 hours ago

In a new study that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have adapted a chemical approach to turn diseased cells into unique manufacturing ...

A new synthetic amino acid for an emerging class of drugs

Aug 31, 2014

Swiss scientists have developed a new amino acid that can be used to modify the 3-D structure of therapeutic peptides. Insertion of the amino acid into bioactive peptides enhanced their binding affinity up to 40-fold. Peptides ...

User comments : 0